Tonix Pharmaceuticals, Inc.’s (NASDAQ: TNXP) interview, Mr. Seth Lederman, CEO


See the full episode at:

New to The Street TV airs the NASDAQ in-studio interview with Tonix Pharmaceuticals, Inc.’s (NASDAQ: TNXP) CEO, Seth Lederman. Talking with “New to The Street” TV Anchor Jane King, Mr. Lederman discusses the Company’s COVID-19 vaccine, antiviral pharmaceutical, skin test, and “Long” COVID-19 novel treatments and products. The Company’s TNX-1800, a live virus vaccine in development, gives long-term protection from COVID, and Seth compares the TNX -1800 live vaccine versus mRNA vaccines. The TNX-3500, an oral antiviral pharmaceutical currently in development, shows in tissue cultures as highly potent compared to competitors’ antiviral products in the marketplace. He sees clinical solid test results from combining the TNX-3500 oral product with Remdesivir. Seth gives viewers information about upcoming studies in other focused products currently in development, including a detox product for cocaine. With about $183M in cash, Seth sees Tonix Pharmaceutical in great shape heading into 2022.

To make sure you never miss a video from New to the Street, click here to subscribe:

Follow New to the Street on Twitter:
Follow New to the Street on Facebook:
Follow New to the Street on Instagram:
Follow New to the Street on Rumble:
About New to the Street:

Subscribe to our Mailing List: